IRIS
RIVARA, Silvia
 Distribuzione geografica
Salva come PNG Salva come JPEG
Continente #
NA - Nord America 7.913
AS - Asia 6.547
EU - Europa 5.323
SA - Sud America 918
AF - Africa 329
Continente sconosciuto - Info sul continente non disponibili 247
OC - Oceania 8
Totale 21.285
Salva come PNG Salva come JPEG
Nazione #
US - Stati Uniti d'America 7.661
SG - Singapore 2.330
CN - Cina 1.801
IT - Italia 1.248
VN - Vietnam 994
FI - Finlandia 786
BR - Brasile 717
IE - Irlanda 692
SE - Svezia 664
DE - Germania 520
HK - Hong Kong 469
UA - Ucraina 341
BD - Bangladesh 282
FR - Francia 240
ZA - Sudafrica 219
NL - Olanda 209
TR - Turchia 178
GB - Regno Unito 166
CA - Canada 158
IN - India 115
RU - Federazione Russa 111
AT - Austria 81
AR - Argentina 68
BE - Belgio 65
MX - Messico 54
CI - Costa d'Avorio 51
IQ - Iraq 51
JP - Giappone 49
PL - Polonia 49
ES - Italia 46
ID - Indonesia 42
KR - Corea 35
PK - Pakistan 30
CO - Colombia 27
CZ - Repubblica Ceca 27
EC - Ecuador 27
PH - Filippine 27
VE - Venezuela 23
JO - Giordania 21
TH - Thailandia 21
MA - Marocco 20
CL - Cile 13
UZ - Uzbekistan 13
LT - Lituania 12
PE - Perù 12
PY - Paraguay 12
SA - Arabia Saudita 11
MY - Malesia 10
EG - Egitto 9
HN - Honduras 9
BO - Bolivia 8
KE - Kenya 8
RO - Romania 8
TW - Taiwan 8
UY - Uruguay 8
HR - Croazia 7
RS - Serbia 7
TN - Tunisia 7
AE - Emirati Arabi Uniti 6
AZ - Azerbaigian 6
IL - Israele 6
NP - Nepal 6
OM - Oman 6
AL - Albania 5
CR - Costa Rica 5
DO - Repubblica Dominicana 5
PS - Palestinian Territory 5
AU - Australia 4
BY - Bielorussia 4
EE - Estonia 4
HU - Ungheria 4
JM - Giamaica 4
NI - Nicaragua 4
SI - Slovenia 4
CY - Cipro 3
ET - Etiopia 3
KZ - Kazakistan 3
LB - Libano 3
LV - Lettonia 3
MD - Moldavia 3
PT - Portogallo 3
SK - Slovacchia (Repubblica Slovacca) 3
SV - El Salvador 3
SY - Repubblica araba siriana 3
AM - Armenia 2
AO - Angola 2
BG - Bulgaria 2
BH - Bahrain 2
DZ - Algeria 2
GR - Grecia 2
GT - Guatemala 2
GY - Guiana 2
KG - Kirghizistan 2
LU - Lussemburgo 2
NO - Norvegia 2
PA - Panama 2
PR - Porto Rico 2
QA - Qatar 2
TG - Togo 2
BB - Barbados 1
Totale 21.016
Salva come PNG Salva come JPEG
Città #
Singapore 1.178
Ashburn 892
San Jose 740
Chandler 711
Dublin 690
Dallas 600
Santa Clara 454
Hong Kong 448
Beijing 433
Jacksonville 384
Ann Arbor 350
Parma 349
Ho Chi Minh City 305
Dearborn 270
Boardman 247
Council Bluffs 238
Hanoi 211
Johannesburg 204
Nanjing 182
Los Angeles 178
New York 177
Munich 137
Izmir 135
Princeton 135
Lauterbourg 129
Shanghai 125
Hefei 109
Wilmington 103
San Mateo 87
Helsinki 71
Toronto 71
Bremen 69
Columbus 68
Milan 67
Vienna 66
Buffalo 64
Brussels 61
São Paulo 59
Shenyang 55
Bologna 54
Moscow 54
Abidjan 51
Hebei 48
Kunming 47
Nanchang 46
Jinan 45
Da Nang 43
Tokyo 43
Turku 43
Frankfurt am Main 42
Haiphong 42
The Dalles 42
Düsseldorf 40
London 38
Guangzhou 36
Montreal 36
Rome 34
Warsaw 33
Modena 32
Changsha 31
Seattle 31
Woodbridge 31
Des Moines 30
Brescia 29
Jiaxing 29
Jakarta 28
Seoul 28
Chicago 27
Houston 26
Chennai 24
Phoenix 24
Pune 24
Stockholm 24
Rio de Janeiro 23
Tianjin 22
Atlanta 21
Baghdad 21
Brooklyn 21
Nuremberg 21
Belo Horizonte 20
Fremont 20
Ankara 19
Naples 19
Orem 19
Amsterdam 18
Denver 18
Mexico City 18
Paris 18
Amman 17
Zhengzhou 17
Norwalk 16
Hangzhou 15
San Francisco 15
Dong Ket 14
Auburn Hills 13
Brno 13
Dhaka 13
Fortaleza 13
Poplar 13
Biên Hòa 12
Totale 12.556
Salva come PNG Salva come JPEG
Nome #
Balancing reactivity and antitumor activity: heteroarylthioacetamide derivatives as potent and time-dependent inhibitors of EGFR 353
Benzisothiazolinone Derivatives as Potent Allosteric Monoacylglycerol Lipase Inhibitors That Functionally Mimic Sulfenylation of Regulatory Cysteines 278
Discovery of a new 1-(phenylsulfonyl)-1H-indole derivative targeting the EphA2 receptor with antiproliferative activity on U251 glioblastoma cell line 261
Antidepressant-like effects of pharmacological inhibition of FAAH activity in socially isolated female rats 242
Antidepressant-like activity and cardioprotective effects of fatty acid amide hydrolase inhibitor URB694 in socially stressed Wistar Kyoto rats 238
2-Aminobenzimidazoles as new potent H3-antagonists 230
Analysis of Structure-Activity Relationships for MT2 Selective Antagonists by Melatonin MT1 and MT2 Receptor Models 222
Amino acid conjugates of lithocholic acid as antagonists of the EphA2 receptor. 221
Social stress-induced depressive-like symptoms and changes in gut microbial and lipidomic profiles are prevented by pharmacological inhibition of FAAH activity in male rats 219
Amino acid derivatives as palmitoylethanolamide prodrugs: Synthesis, in vitro metabolism and in vivo plasma profile in rats 218
Chemical modification of NSC12 leads to a specific FGF-trap with antitumor activity in multiple myeloma 218
Irreversible Inhibition of Epidermal Growth Factor Receptor Activity by 3-Aminopropanamides. 216
Cardioprotective effects of fatty acid amide hydrolase inhibitor URB694, in a rodent model of trait anxiety 214
Dibasic biphenyl H(3) receptor antagonists: Steric tolerance for a lipophilic side chain. 212
New Antimicrobials Targeting Bacterial RNA Polymerase Holoenzyme Assembly Identified with an in Vivo BRET-Based Discovery Platform 212
A sulfonyl fluoride derivative inhibits EGFR L858R/T790M/C797S by covalent modification of the catalytic lysine 208
2-N-Acylaminoalkylindoles: Design and Quantitative Structure-Activity Relationship Studies Leading to MT2-Selective Melatonin Antagonists 207
Combining ligand- and structure-based approaches for the discovery of new inhibitors of the EPHA2-ephrin-A1 interaction 204
Synthesis, biological activity, QSAR and QSPR study of 2/aminobenzimidazole derivatives as potent H3-antagonists 199
UniPR129 is a competitive small molecule Eph-ephrin antagonist blocking in vitro angiogenesis at low micromolar concentrations. 199
Aminobenzimidazoles as new potent H3-antagonists 199
Novel Irreversible Epidermal Growth Factor Receptor Inhibitors by Chemical Modulation of the Cysteine-Trap Portion 196
Application of 3D-QSAR in the Rational Design of Receptor Ligands and Enzyme Inhibitors 195
Alchilammidi tricicliche: ligandi selettivi dei recettori melatoninergici MT1 e MT2 195
Free-Energy Simulations Support a Lipophilic Binding Route for Melatonin Receptors 192
Biphenyl-3-yl alkylcarbamates as fatty acid amide hydrolase (FAAH) inhibitors: steric effects of N-alkyl chain on rat plasma and liver stability 192
Design and structure-activity relationship of amino acid derivatives of lithocholic acid as novel EphA2 antagonists 189
Discovery of novel FGF trap small molecules endowed with anti-myeloma activity 186
The Role of HB-Donor Groups in the Heterocyclic Polar Fragment of H3-Antagonists. I. Synthesis and Biological Assays 185
Validation of a histamine H3 receptor model through structure–activity relationships for classical H3 antagonists 182
Chiral Recognition of Flexible Melatonin Receptor Ligands Induced by Conformational Equilibria 182
Atropisomerism and Conformational Equilibria: Impact on PI3Kδ Inhibition of 2-((6-Amino-9H-purin-9-yl)methyl)-5-methyl-3-(o-tolyl)quinazolin-4(3H)-one (IC87114) and Its Conformationally Restricted Analogs 181
Small molecules targeting the eubacterial β-sliding clamp discovered by combined in silico and in vitro screening approaches 179
N-Acylethanolamine Acid Amidase (NAAA): Mechanism of Palmitoylethanolamide Hydrolysis Revealed by Mechanistic Simulations 177
Synthesis, Structural Elucidation, and Biological Evaluation of NSC12, an Orally Available Fibroblast Growth Factor (FGF) Ligand Trap for the Treatment of FGF-Dependent Lung Tumors 175
2-[N-Acylamino(C1-C3)alkyl]indoles as MT1 Melatonin Receptor Partial Agonists, Antagonists, and Putative Inverse Agonists. 174
Chapter 9: Natural and Synthetic Agents That Target Intracellular Monoacylglycerol Lipase (MGL) Activity 172
JAK3 Inhibitors: Covalent and Noncovalent Interactions of a Cyanamide Group Investigated by Multiscale Free-Energy Simulations 169
Dibasic non-imidazole histamine H3 receptor antagonists with a rigid byphenyl scaffold. 165
N-(Anilinoethyl)amide Melatonergic Ligands with Improved Water Solubility and Metabolic Stability 164
2-Arylmelatonin analogues: Probing the 2-phenyl binding pocket of melatonin MT1 and MT2 receptors 164
QSAR study of 2-aminobenzimidazole derivatives as H3 antagonists 160
Molecular Determinants of EphA2 and EphB2 Antagonism Enable the Design of Ligands with Improved Selectivity 157
Cyclohexylcarbamic Acid 3'- or 4'-Substituted Biphenyl-3-yl Esters of as Fatty Acid Amide Hydrolase Inhibitors: Synthesis, Quantitative Structure-Activity Relationships and Molecular Modelling Studies 157
Tetrahydroquinoline Ring as a Versatile Bioisostere of Tetralin for Melatonin Receptor Ligands 155
Δ5-Cholenoyl-amino acids as selective and orally available antagonists of the Eph-ephrin system 153
An Optimized Workflow for the Discovery of New Antimicrobial Compounds Targeting Bacterial RNA Polymerase Complex Formation 152
Synthesis and 3D-QSAR Analysis of H3 Receptor Antagonists Containing a Neutral Heterocyclic Polar Group 151
Design and synthesis of N-(3,3-diphenylpropenyl)alkanamides as a novel class of high-affinity MT2-selective melatonin receptor ligands. 151
Design and structure-activity relationships of amino acid derivatives of lithocholic acid as novel EphA2 receptor antagonists. 151
Exploiting Free-Energy Minima to Design Novel EphA2 Protein-Protein Antagonists: From Simulation to Experiment and Return 151
N-(Anilinoethyl)amides: design and synthesis of metabolically stable, selective melatonin receptor ligands 150
APPLICATION OF COMPUTATIONAL METHODSTO THE DESIGN OF FATTY ACID AMIDE HYDROLASE(FAAH) INHIBITORS BASED ON A CARBAMICTEMPLATE STRUCTURE 150
Epidermal Growth Factor Receptor Irreversible Inhibitors: Chemical Exploration of the Cysteine-Trap Portion 149
Social stress contagion in rats: Behavioural, autonomic and neuroendocrine correlates 149
N-(2-Oxo-3-oxetanyl)carbamic Acid Esters as N-Acylethanolamine Acid Amidase Inhibitors: Synthesis, Structure–Activity and Structure–Property Relationships. 149
Comparative Analysis of Virtual Screening Approaches in the Search for Novel EphA2 Receptor Antagonists 148
Toward the Definition of Stereochemical Requirements for MT(2)-Selective Antagonists and Partial Agonists by Studying 4-Phenyl-2-propionamidotetralin Derivatives. 145
Anxiolytic effects of the melatonin MT2 receptor partial agonist UCM765: Comparison with melatonin and diazepam. 145
Development of a GPCR model for SAR interpretation of classical and new H3 antagonists 144
Synthesis and biological evaluation of new non-imidazole H(3)-receptor antagonists of the 2-aminobenzimidazole series 143
Design and SAR Analysis of Covalent Inhibitors Driven by Hybrid QM/MM Simulations 142
Experimental and Theoretical Analysis of the Interaction of (±)-cis-Ketoconazole with b-Cyclodextrin in the presence of (+)-L-Tartaric Acid 141
Synthesis and biological assays of new H3-antagonists with imidazole and imidazoline polar groups 139
Metadynamics for perspective drug design: Computationally driven synthesis of new protein-protein interaction inhibitors targeting the EphA2 receptor 139
Computer-Aided Design of Novel Antagonists of the EphA2 Receptor 138
ST7612AA1, a thioacetate-ω(γ-lactam carboxamide) derivative selected from a novel generation of oral HDAC inhibitors 138
Fatty Acid Amide Hydrolase (FAAH), Acetylcholinesterase (AChE), and Butyrylcholinesterase (BuChE): Networked Targets for the Development of Carbamates as Potential Anti-Alzheimer's Disease Agents 138
MT2 selective melatonin receptor antagonists: design and structure-activity relationships 137
Identification of bivalent ligands with melatonin receptor agonist and fatty acid amide hydrolase (FAAH) inhibitory activity that exhibit ocular hypotensive effect in the rabbit 137
Mechanistic Modeling of Monoglyceride Lipase Covalent Modification Elucidates the Role of Leaving Group Expulsion and Discriminates Inhibitors with High and Low Potency 136
Long-lasting inhibition of EGFR autophosphorylation in A549 tumor cells by intracellular accumulation of non-covalent inhibitors 136
Free-energy studies reveal a possible mechanism for oxidation-dependent inhibition of MGL 135
Histamine H3-antagonists: the basicity of the polar group in quantitative structure-activity and structure-property relationship 134
Metadynamics Simulations Distinguish Short- and Long-Residence-Time Inhibitors of Cyclin-Dependent Kinase 8. 134
Highly Potent and Selective MT2 Melatonin Receptor Full Agonists from Conformational Analysis of 1-Benzyl-2-acylaminomethyl-tetrahydroquinolines 133
Tricyclic Alkylamides as Melatonin Receptor Ligands with Antagonist or Inverse Agonist Activity 133
In silico drug discovery of melatonin receptor ligands with therapeutic potential 132
Synthesis, Enantiomeric Resolution, and Structure-Activity Relationship Study of a Series of 10,11-Dihydro-5H-Dibenzo[a,d]cycloheptene MT(2) Receptor Antagonists. 132
Pharmacokinetics, pharmacodynamics and safety studies on URB937, a peripherally restricted fatty acid amide hydrolase inhibitor, in rats 132
Binding and unbinding of potent melatonin receptor ligands: Mechanistic simulations and experimental evidence 130
Three-Dimensional Quantitative Structure-Activity Relationship Studies on Selected MT1 and MT2 Melatonin Receptor Ligands: Requirements for Subtype Selectivity and Intrinsic Activity Modulation 130
Synthesis and structure-activity relationships for biphenyl H3 receptor antagonists with moderate anti-cholinesterase activity. 130
New classes of potent heparanase inhibitors from ligand-based virtual screening 128
Synthesis and Structure-Activity Relationships of Amino Acid Conjugates of Cholanic Acid as Antagonists of the EphA2 Receptor. 127
Novel Benzazole Derivatives Endowed with Potent Antiheparanase Activity 126
Synthesis and characterization of the first inhibitor of: N -acylphosphatidylethanolamine phospholipase D (NAPE-PLD) 122
Design, synthesis and SAR of alkylcarbamic acid aryl esters, a new class of fatty acid amide hydrolase inhibitors 121
Strategies leading to MT2 selective melatonin receptor antagonists. 121
In vitro characterization of potency, affinity and selectivity of H3-antagonists: from thioperamide to thioperamide unrelated derivatives 121
Homology models of melatonin receptors: challenges and recent advances. 120
H3-receptor antagonists: Synthesis and structure relationships of para- and meta-substituted 4(5)-phenyl-2-((2-(4(5)-imidazolyl)ethyl)thio)imidazoles 119
Investigating drug-gut microbiota interactions: reductive and hydrolytic metabolism of oral glucocorticoids by in vitro artificial gut microbiota 118
Melatonin Receptor Agonists: SAR and Applications to the Treatment of Sleep-Wake Disorders. 118
Structure-property relationships of a class of carbamate-based fatty acid amide hydrolase (FAAH) inhibitors: chemical and biological stability 118
Synthesis, Pharmacological Evaluation and Structure-Activity Relationships of Benzopyran Derivatives with Potent SERM Activity 117
Plasma concentration and brain penetration of the H3-receptor antagonist Thioperamide in rats 117
Antiproliferative and pro-apoptotic activity of melatonin analogues on melanoma and breast cancer cells 117
Melatonin receptor structure and signaling 114
Structure-Property Relationships on Histamine H3-Antagonists: Binding of Phenyl-substituted Alkylthioimidazole Derivatives to Rat Plasma Proteins 113
Totale 16.407
Salva come PNG Salva come JPEG
Categoria #
all - tutte 73.820
article - articoli 0
book - libri 0
conference - conferenze 0
curatela - curatele 0
other - altro 0
patent - brevetti 0
selected - selezionate 0
volume - volumi 0
Totale 73.820
Salva come PNG Salva come JPEG


Totale Lug Ago Sett Ott Nov Dic Gen Feb Mar Apr Mag Giu
2021/2022737 0 25 13 87 51 19 70 98 51 59 56 208
2022/20232.764 303 265 170 212 275 333 29 157 848 38 92 42
2023/20241.050 58 72 29 37 77 249 74 90 57 76 94 137
2024/20253.696 82 190 244 221 317 384 186 214 491 382 347 638
2025/20268.454 703 922 1.102 806 1.075 441 827 264 981 614 451 268
2026/2027444 174 270 0 0 0 0 0 0 0 0 0 0
Totale 21.285